IDH1 and acute myeloid leukemia: To validate prospectively this finding, we treated xenotransplanted NPM1-mutated AML cells also harboring mutations in DNMT3A, IDH1, and FLT3 with a combination of the anthracycline doxorubicin and cytarabine at maximal tolerated dose, ruxolitinib or the triplet combination (Fig. 6b).